Table 4 Summary of molecular findings and final classification of the cases.

From: Re-evaluating tumors of purported specialized prostatic stromal origin reveals molecular heterogeneity, including non-recurring gene fusions characteristic of uterine and soft tissue sarcoma subtypes

Case	Original diagnosis	Morphologic pattern^a	Most relevant molecular alteration(s)	Final classification
1	PSS	Patternless	NAB2-STAT6 fusion	Solitary fibrous tumor, high risk
2	PSS	Short fascicles	TPM3-NTRK1 fusion	Sarcoma with TPM3-NTRK1 rearrangement, intermediate grade
3	PSS	Patternless/Epithelioid	BCOR-MAML3 fusion	Sarcoma with BCOR-MAML3 rearrangement, intermediate grade
4	PSS	Epithelioid/Storiform	Biallelic inactivation of TP53, ATRX mutation, AR amplification, and MAPK4 amplification	Unclassified sarcoma, intermediate grade
5	PSS	Patternless/Epithelioid	Biallelic inactivation of TP53, ATRX mutation, and homozygous RB1 deletion	Unclassified sarcoma, high grade
6	PSS	Short fascicles/Storiform	Biallelic inactivation of PTEN and RASA1, homozygous deletion of CDKN2A/CDKN2B, homozygous deletion of NF1 and MET1 amplification	Unclassified sarcoma, low grade
7	PSS	Fibrosarcomatous/Soriform	KAT6B and SUFU mutations	Unclassified sarcoma, intermediate grade
8	PSS	Short fascicles	BCORL1 and TSC2 mutations	Unclassified sarcoma, high grade
9	PSS	Short fascicles/Patternless	Biallelic inactivation of ARID1A	Unclassified sarcoma, high grade
10	PSS	Short fascicles	NA (failed sequencing/low DNA)	Unclassified sarcoma, intermediate grade
11	PSS^b	Patternless/Epithelioid^b	Biallelic inactivation of both TP53 and CHEK2	Unclassified sarcoma, intermediate grade
	STUMP^b	Myxoid^b	Biallelic incativation of TP53 and CHEK2 mutation
12	STUMP	Patternless	JAZF1-SUZ12 fusion and biallelic inactivation of BCOR	Low-grade endometrial stromal sarcoma-like sarcoma
13	STUMP	Phyllodes	RGPD2-FOXO1 rearrangement and HOXB13 amplification	Mesenchymal tumors of uncertain malignant potential
14	STUMP	Degenerative atypia	Biallelic inactivation of TP53 and PALB2 rearrangement	Unclassified sarcoma, low grade
15	STUMP^c	Phyllodes	TP53 mutation	Unclassified sarcoma, low grade^c
16	STUMP	Phyllodes	Biallelic inactivation of TP53 and ATR mutation	Unclassified sarcoma, low grade
17	STUMP	Phyllodes	KMT2D mutation	Mesenchymal tumor of uncertain malignant potential
18	STUMP	Hypercellular	RSPO insertion/deletion	Mesenchymal tumor of uncertain malignant potential
19	STUMP	Hypercellular	POT1 mutation, MDM2 amplification, CDK4 amplification, ERBB3 amplification	Mesenchymal tumor of uncertain malignant potential
20	STUMP	Myxoid	Homozygous CHEK2 deletion	Mesenchymal tumor of uncertain malignant potential
21	STUMP	Myxoid	None found	Mesenchymal tumor of uncertain malignant potential
22	STUMP	Hypercellular	CIC-SERPINF fusion?^d	Mesenchymal tumor of uncertain malignant potential
23	STUMP	Hypercellular	NA (failed sequencing/low DNA)	Mesenchymal tumor of uncertain malignant potential
24	STUMP	Hypercellular	NA (failed sequencing/low DNA)	Mesenchymal tumor of uncertain malignant potential
25	STUMP	Phyllodes	NA (failed sequencing/low DNA)	Mesenchymal tumor of uncertain malignant potential

NA not available/applicable, STUMP stromal tumor of uncertain malignant potential, PSS prostatic stromal sarcoma.
^aAs descibed in Herawi et al. [1].
^bIn the manuscript, this case was counted as a PSS; therefore, only the histopathologic features of the PSS component were quantified.
^cThis case was initially diagnosed as STUMP, but later developed intraperitoneal metastases.
^dOnly detected by RNA sequencing (low-confidence call, likely stochastic).

Back to article page

Table 4 Summary of molecular findings and final classification of the cases.

Search

Quick links